Sanofi SA SNY on Tuesday agreed to amass Vicebio Ltd, a privately held biotechnology firm headquartered in London, U.Ok.
The acquisition brings an early-stage mixture vaccine candidate for respiratory syncytial virus (RSV) and human metapneumovirus (hMPV), each respiratory viruses, and expands the capabilities in vaccine design and growth with Vicebio’s ‘Molecular Clamp’ expertise.
The vaccine candidate enhances Sanofi’s place within the respiratory vaccines house, the place the corporate is current in flu and RSV prevention. It permits Sanofi to supply elevated doctor and affected person selection in RSV and hMPV by including a non-mRNA vaccine to its pipeline.
Additionally Learn: GSK Seeks FDA Nod To Broaden RSV Vaccine For Youthful At-Threat Adults
The acquisition additionally provides ‘Molecular Clamp,’ a expertise stabilizing viral proteins of their native form, enabling the immune system to acknowledge and reply to them extra successfully.
The method permits faster growth of absolutely liquid mixture vaccines saved at normal refrigeration temperatures (2–8°C), eliminating the necessity for freezing or freeze-drying, thereby simplifying manufacturing and distribution.
Moreover, absolutely liquid vaccines may be made accessible in prefilled syringes, enhancing ease of use, security, and operational effectivity throughout healthcare settings.
Beneath the phrases of the settlement, Sanofi would purchase all of Vicebio’s share capital for a complete upfront fee of $1.15 billion, with potential milestone funds of as much as $450 million based mostly on growth and regulatory achievements.
The transaction is anticipated to shut within the fourth quarter of 2025, topic to customary closing circumstances, together with receipt of regulatory approvals. The acquisition is not going to have a big affect on Sanofi’s monetary steering for 2025.
Trending Funding Alternatives
Vicebio’s pipeline contains VXB-241, a bivalent vaccine candidate focusing on RSV and hMPV, at the moment in an exploratory part 1 examine in older adults, and VXB-251, a preclinical trivalent vaccine candidate focusing on RSV, hMPV, and parainfluenza virus Sort 3 (PIV3).
This acquisition reinforces Sanofi’s dedication to innovation in respiratory vaccines. In June, Sanofi stated it’s delivery Beyfortus (nirsevimab) beginning in early Q3 to make sure broad availability nicely forward of the 2025-2026 RSV season, which generally begins in November and runs by way of March.
Sanofi, in collaboration with its associate AstraZeneca plc AZN, has tripled manufacturing capability and doubled the variety of manufacturing websites because the launch of Beyfortus in 2023.
This acquisition follows one other vital transfer by Sanofi in June 2025, when it agreed to amass Blueprint Medicines Company BPMC for roughly $9.1 billion.
That acquisition included Ayvakit/Ayvakyt (avapritinib), a uncommon immunology illness medication accepted within the U.S. and the EU, together with a promising superior and early-stage immunology pipeline.
Worth Motion: SNY inventory is buying and selling increased by 1.42% to $48.61 ultimately test Tuesday.
Learn Subsequent:
Picture by HJBC through Shutterstock
